Chimerix to Report Fourth Quarter and Year End 2019 Financial Results and Provide an Operational Update on February 25, 2020
February 18 2020 - 8:00AM
Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on
accelerating the development of medicines to treat cancer and other
serious diseases, today announced that it will host a live
conference call and audio webcast on Tuesday, February 25, 2020 at
8:30 a.m. ET to report financial results for the fourth quarter and
full-year ended December 31, 2019, and to provide a business
overview.
To access the live conference call, please dial (877) 354-4056
(domestic) or (678) 809-1043 (international) at least five minutes
prior to the start time, and refer to conference ID 1397800. A live
audio webcast of the call will also be available on the Investors’
section of the Company's website, www.chimerix.com. An archived
webcast will be available on the Chimerix website approximately two
hours after the event.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. The two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
Dociparstat sodium is a potential first-in-class
glycosaminoglycan compound derived from porcine heparin that has
low anticoagulant activity but retains the ability to inhibit
activities of several key proteins implicated in the retention and
viability of AML blasts and leukemic stem cells in the bone marrow
during chemotherapy (e.g., CXCL12, selectins, HMGB1,
elastase). Mobilization of AML blasts and leukemic stem cells
from the bone marrow has been associated with enhanced
chemosensitivity and may be a primary mechanism accounting for the
observed increases in EFS and OS in Phase 2 with DSTAT versus
placebo. Randomized Phase 2 data suggest that DSTAT may also
accelerate platelet recovery post-chemotherapy via inhibition of
platelet factor 4, a negative regulator of platelet production that
impairs platelet recovery following chemotherapy. BCV is an
antiviral drug candidate in development as a medical countermeasure
for smallpox. For further information, please visit the Chimerix
website, www.chimerix.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
that are subject to risks and uncertainties that could cause actual
results to differ materially from those projected. Forward-looking
statements include those relating to, among other things,
Chimerix’s ability to develop BCV as a medical countermeasure for
smallpox; Chimerix’s ability to submit and/or obtain regulatory
approvals for BCV; and Chimerix’s ability to enter into a
procurement contract for BCV as a medical countermeasure. Among the
factors and risks that could cause actual results to differ
materially from those indicated in the forward-looking statements
are risks that BCV may not obtain regulatory approval from
the FDA or such approval may be delayed or conditioned;
risks that development activities related to BCV may not be
completed on time or at all; Chimerix’s reliance on a sole source
third-party manufacturer for drug supply; risks that ongoing or
future trials may not be successful or replicate previous trial
results, or may not be predictive of real-world results or of
results in subsequent trials; risks and uncertainties relating to
competitive products and technological changes that may limit
demand for our drugs; risks that our drugs may be precluded from
commercialization by the proprietary rights of third parties; risks
related to procurement of brincidofovir for the treatment of
smallpox and additional risks set forth in the Company's filings
with the Securities and Exchange Commission. These
forward-looking statements represent the Company's judgment as of
the date of this release. The Company disclaims, however, any
intent or obligation to update these forward-looking
statements.
CONTACT:Investor
Relations:
Michelle LaSpaluto 919 972-7115 ir@chimerix.com Will O’Connor Stern
Investor Relations will@sternir.com 212-362-1200
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024